DOP56 Ustekinumab maintained clinically meaningful improvement in health-related quality of life in patients with moderate to severe ulcerative colitis: Results from the UNIFI long-term extension
William J. Sandborn(University of San Diego), Silvio Danese(IRCCS Ospedale San Raffaele), Yiying Zhou(Janssen (United States)), David Rowbotham(University of Auckland), Colleen Marano(Johnson & Johnson (United States)), H Zhang(Janssen (United States)), Chenglong Han(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Rupert W. Leong(The University of Sydney)
Cited by 3
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k